Ardelyx 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Ardelyx reported third-quarter 2026 total product revenue of $125.5 million, up 19% from $105.5 million in the same period last year.
- It's Rella revenue was $96.3 million, up 23% compared with Q3 2025, with growth in total writers and prescriptions and demand reaching all-time highs.
- Exposa revenue was $29.2 million, up 7% compared with Q3 2025; paid prescriptions grew 22% compared with the same quarter in 2025.
- Research and development expenses were $25.2 million versus $18.1 million in the same period in 2025, primarily reflecting investment in the Excel Phase 3 clinical trial in CIC.
- Selling, general and administrative expenses were $93.9 million versus $83.6 million in the same period in 2025, reflecting investments in the FRM team, sales force, and DTC initiative.
- Net loss was $700,000 compared with $1 million in the same period in 2025; the quarter ended with $285.3 million in cash, cash equivalents, and short-term investments.
- The company said its gross profit margin is greater than 95% and its revenue is funding operations and the pipeline.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Welcome to the IBSRELA third quarter 2026 earnings call. All participants will be in a listen-only mode. I would now like to turn the conference over to Lisa Caperelli, SVP, Investor Relations and Corporate Communication. Lisa, you may begin. Thank you, Paul.
Good afternoon, and welcome to our third quarter 2026 financial results and business update call. Earlier today, we issued our earnings release, which can be found on the investor section of our website at ardelyx.com. Slides that accompany today's call can also be found on our website. On today's call, I am joined by Mike Raab, President and CEO of Ardelyx, and Sue Hohenleitner, our Chief Financial Officer. Before we begin, I'd like to remind you that some of the statements made during the call today are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
These statements involve a number of risks and uncertainties that may cause our actual results to differ materially from those expressed or implied, including those described in our annual report on Form 10-K, our quarterly report on Form 10-Q, which was filed today, and from time to time in our other documents filed with the SEC. These forward-looking statements speak only as of today's date, and while we may elect to update these forward-looking statements in the future, we specifically disclaim any obligation to do so, even if our views change. I will now pass the call over to Mike.
Mike? Thank you, Lisa. Good afternoon, everyone, and thank you for joining us today.
Ardelyx is a company focused on developing and commercializing innovative medicines, and today, with IBSRELA and XPHOZAH, we have two first-in-class medicines that in the third quarter generated over $125 million in revenue, up 19% from a year ago. With a strengthened financial position and a robust patent portfolio, our products are well-positioned for significant long-term growth. Our focus is now to leverage that foundation and to build a pipeline to create long-term value. Our third quarter's performance bolsters our confidence as we focus on executing on our priorities: accelerating the growth of IBSRELA, maintaining XPHOZAH's momentum, building and expanding our pipeline, and delivering strong financial results. Starting with IBSRELA. In Q3, IBSRELA generated revenue of $96.3 million, representing 23% year-over-year growth.
HCP confidence in IBSRELA remains high, with demand reaching all-time highs as the number of total writers, total prescriptions, and market share continues to grow. This growth supports our full-year guidance and reinforces our long-term view of achieving $1 billion in annual revenue. Critical to that is our ongoing work to thoughtfully eliminate the payer friction HCPs and patients experience when first starting IBSRELA. In our efforts to alleviate some of this friction in the third quarter, we began to see progress that gave us confidence that these initiatives are beginning to take hold. As we've noticed in the past, IBSRELA is a promotionally sensitive brand, and mid-year, we expanded our sales force to increase reach and frequency to our target HCPs and continue to build the top of the funnel demand. In addition, we doubled our field reimbursement team to help HCPs navigate the prior authorization landscape.
We're also continuing our efforts to transition writers to utilize the IBSRELA Pharmacy Network, as we know that when the IPN is utilized, patients experience two to three higher fulfillment rates, faster fill times, and at least one additional refill per patient on an annual basis. We will continue to assess all tools at our disposal to streamline the prior authorization process, such as how best to leverage digital and AI tools. Our teams are executing at a high level, translating into notable results with total prescriptions growing. on September 1st, we embarked on a highly targeted effort to raise awareness of IBSRELA with IBS-C patients and launched our first direct-to-consumer ad. This highly targeted ad has a clear call to action and is intended to reach more than 10 million people through outlets such as Netflix, Hulu, Prime Video, and Disney+.
In the testing phase of the ad with IBS-C patients, 91% of them said that they would ask their doctor if IBSRELA was right for them. In a short time, we've seen that the campaign has delivered meaningful impressions and is driving an increase in traffic to our consumer-focused website. These are early positive indicators, and we continue to monitor how this increased awareness translates into new patient starts. As you know, the IBS-C market is very large. Over 7 million prescriptions are written for IBS-C-approved medications per year, and more than 70% of patients continue to experience persistent symptoms, with IBSRELA being an important alternative for millions of dissatisfied IBS-C patients. In addition to providing benefits to IBS-C patients, our real-world data demonstrated that there is also the potential of generating significant savings in healthcare services for IBS-C patients when they are treated with IBSRELA.
A few weeks ago, at the American College of Gastroenterology Annual Scientific Meeting, we presented real-world data showing that when on IBSRELA, GI-related healthcare resource utilization drops, primarily driven by fewer doctor visits and labs. Taken together, IBSRELA not only provides symptom relief for IBS-C patients, but may also reduce broader healthcare resource burden associated with the disease. The fundamentals of the IBSRELA business remain very strong, and by staying focused on execution and improving patient access, we are positioned to drive continued adoption and create meaningful benefits for patients. Now, moving on to XPHOZAH. Revenue in Q3 was $29.2 million, representing 7% year-over-year growth, and we continue to see growth in paid prescriptions of 22% compared to the same quarter in 2025. The need for XPHOZAH remains high.
In the U.S., there are more than 550,000 adults with CKD on dialysis, with more than 80% of them requiring treatment for hyperphosphatemia. Yet nearly 70% of those patients struggle to reach and maintain target phosphorus levels. A few weeks ago at the American Society of Nephrology Kidney Week, we presented real-world evidence supporting XPHOZAH's ability to consistently reduce serum phosphate. We also presented data highlighting the difficulty of managing hyperphosphatemia and the serious mortality morbidity associated with cumulative phosphate burden. Together, these findings continue to reinforce the need for XPHOZAH, a differentiated treatment that can help dialysis patients reach and maintain target phosphorus levels. As we've discussed before, the dialysis reimbursement environment is complex, and we are taking thoughtful and measured approach to help ensure that XPHOZAH continues to be a positive contributor. Now, pivoting to our pipeline.
tenapanor is our foundation and will enable us to grow our pipeline. Our most advanced program with IBSRELA is our ACCEL phase III clinical trial in patients with chronic idiopathic constipation, or CIC. Today, we announced that we have fully enrolled the trial ahead of schedule. The interest and pace of enrollment in the trial underscores the enthusiasm on the part of treating physicians for a new option for their patients experiencing the significant burden of CIC. Our confidence in the success of IBSRELA in CIC patients is, in large part, based on data from our IBS-C clinical development program. Patients with CIC and IBS-C have overlapping symptoms. We believe that expanding the use of IBSRELA to CIC will provide an additional option for patients currently underserved by their CIC treatments.
In October, we convened a medical advisory board of HCPs to elicit their feedback on the CIC treatment landscape and our phase III trial design. Three things stood out from that discussion that I'd like to share with you. First, the need is real, as CIC patients cycle through multiple over-the-counter products before seeking care, and like IBS-C patients, often arrive treatment-experienced. Second, there is a solid clinical rationale. CIC and IBS-C overlap substantially, and we believe that the clinical efficacy observed with tenapanor in IBS-C could translate to patients with CIC. Third, the trial has been well-received, as evidenced by the faster-than-projected enrollment in the ACCEL trial. We are encouraged by the progress we've made and look forward to reporting top-line results in the second half of 2027.
Finally, we are in a strong financial position with our $285 million of cash, with our revenue funding our operations and supporting our path to profitability in 2027. With that, I will now turn the call over to Sue to discuss the quarter's financials in detail.
Sue? Thank you, Mike. Three points stand out for me from our third-quarter results.
First, IBSRELA continues to drive our growth, with revenue up 23% year-over-year. Second, we're turning that growth into financial progress. Our net loss narrowed to $700,000, and we ended the quarter with $285.3 million in cash. Third, based on the continued strength and performance, we're reaffirming our full-year guidance for both products and for operating expenses. Now let me walk you through the numbers. In the third quarter, our total product revenue was $125.5 million compared to $105.5 million in the same period last year, representing 19% growth year-over-year. IBSRELA Q3 revenue was $96.3 million, an increase of 23% compared to Q3 2025. IBSRELA revenue growth reflects growing demand and an increase in total writers and total prescriptions.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
15 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
